It is estimated that less than one in ten people with dementia are eligible for treatment with Lecanemab or Leqembi, the ...

On Thursday, the EMA (European Medicines Agency) approved the long-awaited treatment after initially blocking it in July, ...

The drug - in the form of its Mounjaro KwikPen device - was approved by the UK's Medicines and Healthcare products Regulatory Agency (MHRA ... in Wegovy and Ozempic - were presented at the European ...

A new study reveals that more than half of cancer drugs approved by the FDA under accelerated pathways are not authorized in ...

EMA committee recommends approval of Eisai & Biogen’s lecanemab to treat early Alzheimer’s disease: Tokyo Saturday, November 16, 2024, 13:00 Hrs [IST] Eisai Co., Ltd. and Biog ...

InflaRx (IFRX) has released an update. InflaRx has received a positive opinion from the European Medicines Agency’s CHMP for GOHIBIC, a ...

InflaRx (IFRX) announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive ...

EMA human medicine committee recommends approval of Sanofi’s Sarclisa to treat transplant-ineligible newly diagnosed multiple myeloma: Paris Saturday, November 16, 2024, 09:00 H ...

Lecanemab is the first treatment for Alzheimer’s disease licensed for use in Great Britain that shows some evidence of ...

A groundbreaking medication designed to delay the onset of Alzheimer's has received approval for use within the EU. The drug, ...

European Medicines Agency and other governmental regulations applicable to product approvals; changes in the regulatory ...

InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced that the Committee for Medicinal Products for Human ...